BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gomes AC, Griffiths PD, Reeves MB. The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. Vaccines (Basel) 2019;7:E67. [PMID: 31319553 DOI: 10.3390/vaccines7030067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ai Y, Wu C, Zhang M, Jaijyan DK, Liu T, Zan L, Li N, Yu W, Wang Y, Yuan X, Li C, Zheng W, Zhu H, Liao H. Neutralization Epitopes in Trimer and Pentamer Complexes Recognized by Potent Cytomegalovirus-Neutralizing Human Monoclonal Antibodies. Microbiol Spectr 2022. [DOI: 10.1128/spectrum.01393-22] [Reference Citation Analysis]
2 Mancebo FJ, Parras-Moltó M, García-Ríos E, Pérez-Romero P. Deciphering the Potential Coding of Human Cytomegalovirus: New Predicted Transmembrane Proteome. Int J Mol Sci 2022;23:2768. [PMID: 35269907 DOI: 10.3390/ijms23052768] [Reference Citation Analysis]
3 Maple PAC. Multiple Sclerosis, Viruses, and New Vaccines. Neurol Int 2021;13:712-4. [PMID: 34940754 DOI: 10.3390/neurolint13040068] [Reference Citation Analysis]
4 Eberhard S, Vietzen H, Görzer I, Jaksch P, Puchhammer-Stöckl E. Analysis and Fine Specificity of the HCMV-Specific Cell-Free and Cell-Associated Antibody-Dependent Cellular Phagocytosis (ADCP) Responses in Lung Transplant Recipients. Int J Mol Sci 2021;22:8206. [PMID: 34360986 DOI: 10.3390/ijms22158206] [Reference Citation Analysis]
5 Perotti M, Marcandalli J, Demurtas D, Sallusto F, Perez L. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. PLoS Pathog 2020;16:e1009169. [PMID: 33370407 DOI: 10.1371/journal.ppat.1009169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Singh T, Otero CE, Li K, Valencia SM, Nelson AN, Permar SR. Vaccines for Perinatal and Congenital Infections-How Close Are We? Front Pediatr 2020;8:569. [PMID: 33384972 DOI: 10.3389/fped.2020.00569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Schleiss MR, Diamond DJ. Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection. Vaccines (Basel) 2020;8:E526. [PMID: 32937764 DOI: 10.3390/vaccines8030526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
8 Theobald SJ, Kreer C, Khailaie S, Bonifacius A, Eiz-Vesper B, Figueiredo C, Mach M, Backovic M, Ballmaier M, Koenig J, Olbrich H, Schneider A, Volk V, Danisch S, Gieselmann L, Ercanoglu MS, Messerle M, Kaisenberg CV, Witte T, Klawonn F, Meyer-Hermann M, Klein F, Stripecke R. Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV. PLoS Pathog 2020;16:e1008560. [PMID: 32667948 DOI: 10.1371/journal.ppat.1008560] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Perotti M, Perez L. Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV. Viruses 2019;12:E35. [PMID: 31905677 DOI: 10.3390/v12010035] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]